INTRODUCTION {#s1}
============

Bladder cancer (BC) is one of the most frequently diagnosed malignancies and is a common cause of cancer-related mortality worldwide. Approximately 25% of the bladder cancers are found to be muscle invasive (MIBC) with a 5-year survival proportion of 33% \[[@R1]\]. Therefore, developing appropriate and effective biomarkers to predict clinical outcome is crucial for elucidating the mechanism underlying metastasis and recurrence in MIBC, resulting in discovery of novel therapeutic agents.

Platelets play a pivotal role in cancer progression and metastasis. There is emerging evidence to suggest that platelets mediate tumor cell growth, angiogenesis, and dissemination \[[@R2]\]. Increased platelets are correlated with a decrease in overall survival and poorer prognosis in various types of cancer, including pancreatic cancer, gastric cancer, colorectal cancer, endometrial cancer, and ovarian cancer \[[@R3]--[@R7]\]. However, platelet count is determined by the balance between the rate of production and consumption of platelets. A normal platelet count could conceal the presence of highly hypercoagulative and pro-inflammatory cancer phenotypes in the presence of efficient compensatory mechanisms \[[@R8]\].

Mean platelet volume (MPV), the most commonly used measure of platelet size, is a surrogate marker of platelet activation \[[@R9]\]. Altered MPV levels were found in gastric cancer, ovarian cancer, lung cancer, colon cancer, and breast cancer \[[@R10]--[@R14]\]. In addition, MPV is associated with the prognosis in patients with non-small cell lung cancer and multiple myeloma \[[@R15], [@R16]\]. However, its clinical implications in MIBC have not been well defined. Therefore, the purpose of the current study was to evaluate the association of MPV levels with prognosis in MIBC cases.

RESULTS {#s2}
=======

Between Jan, 2009 and Dec, 2009, a total of 218 MIBC patients were enrolled in this study. Among the 218 patients, 46 (21.1) were women and 172 (78.9) were men, and the median age was 63.2 ± 9.0 years (range 31-82).

A ROC curve for OS prediction was plotted to verify the optimal cut-off value for MPV, which was 9.1 fL (Figure [1](#F1){ref-type="fig"}). It demonstrated that MPV predicts cancer prognosis with a sensitivity of 77.6 % and a specificity of 40.0 % (AUC = 0.591, 95 % CI: 0.522-0.657, p = 0.031). Then, patients were divided into 2 groups: patients with MPV ≤ 9.1 fL and patients with MPV \> 9.1 fL. There were 141 (64.7 %) patients with MPV ≤ 9.1 fL and 77 (35.3 %) patients with MPV \> 9.1 fL.

![Optimized cut-off value was determined for MPV using standard ROC curve analysis](oncotarget-08-68115-g001){#F1}

The relationships between MPV and clinical characteristics were shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Our study revealed that MPV was associated with T stage and histology grade. However, no significant differences were found between the groups with regard to age, gender, multiplicity, growth pattern, distant metastasis, and lymphovascular invasion.

###### Baseline characteristics of the patients according to MPV levels

  Variables                 Total        MPV \> 9.1   MPV ≤ 9.1    P value
  ------------------------- ------------ ------------ ------------ ----------
  Age (years)                                                      0.657
   ≤ 65                     123 (56.4)   45 (58.4)    78 (55.3)    
   \> 65                    95 (43.6)    32 (41.6)    63 (44.7)    
  Gender                                                           0.665
   Male                     172 (78.9)   62 (80.5)    110 (78.0)   
   Female                   46 (21.1)    15 (19.5)    31 (22.0)    
  T stage                                                          \< 0.001
   T2                       144 (66.1)   53 (9.2)     91 (19.2)    
   T3                       26 (11.9)    11 (50.4)    15 (50.4)    
   T4                       48 (22.0)    13 (40.4)    35 (30.4)    
  Histology grade                                                  0.028
   G1+G2                    114 (52.3)   48 (62.3)    66 (46.8)    
   G3                       104 (47.7)   29 (37.7)    75 (53.2)    
  Multiplicity                                                     0.474
   Solitary                 126 (57.8)   47 (61.0)    79 (56.0)    
   Multifocal               92 (42.2)    30 (39.0)    62 (44.0)    
  Growth pattern                                                   0.699
   Papillary                84 (38.5)    31 (40.3)    53 (37.6)    
   Non-papillary            134 (61.5)   46 (59.7)    88 (62.4)    
  Lymphovascular invasion                                          0.081
   Yes                      82 (37.6)    23 (29.9)    59 (41.8)    
   No                       136 (62.4)   54 (70.1)    82 (58.2)    

MPV, mean platelet volume.

###### Baseline characteristics of the patients according to MPV levels

  Variables                   MPV \> 9.1         MPV ≤ 9.1          P value
  --------------------------- ------------------ ------------------ ----------
  Age (years)                 62.2 (9.5)         63.8 (8.7)         0.189
  Gender (male, %)            62 (80.5)          110 (78.0)         0.665
  Smoker (n, %)               15 (19.5)          23 (16.3)          0.556
  Drinking (n, %)             8 (10.4)           16 (11.3)          0.829
  BMI (kg/m^2^)               23.4(3.0)          23.5 (3.1)         0.781
  FPG (mmol/L)                5.10 (4.80-5.55)   5.00 (4.70-5.30)   0.040
  WBC (×10^9^/L)              7.25 (2.87)        7.06 (2.53)        0.615
  Neutrophils (×10^9^/L)      4.54 (2.49)        4.60 (2.35)        0.876
  Lymphocytes (×10^9^/L)      2.03 (0.71)        1.80 (0.56)        0.017
  Hemoglobin (g/dl)           138.2 (17.0)       133.5 (18.4)       0.068
  Platelet count (×10^9^/L)   199.2 (51.1)       223.1 (65.7)       0.003
  PDW (%)                     17.2 (1.2)         16.7 (0.8)         \< 0.001
  NLR                         2.80 (2.67)        2.70 (2.17)        0.760
  PLR                         119.1 (58.3)       128.3 (52.6)       0.238

Data are expressed as means (SD) or median (IQR). FPG, fasting plasma glucose; WBC, white blood cell; BMI, body mass index; MPV, mean platelet volume; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

With a median follow up of 60 months, 58 (26.6 %) patients had death events. Patients with MPV ≤ 9.1 fL had a significantly shorter 5-year OS than patients with MPV \> 9.1 fL (68.1 % vs. 83.1 %, p = 0.007). The Kaplan-Meier OS curves of the normal versus reduced MPV showed a significant separation (Figure [2](#F2){ref-type="fig"}).

![Kaplan--Meier analysis of overall survival in MIBC patients](oncotarget-08-68115-g002){#F2}

In univariate analysis, age (categorical variable), MPV (categorical variable), histology grade, lymphovascular invasion, multiplicity, and growth pattern were significant predictors of OS (Table [3](#T3){ref-type="table"}). NLR (p = 0.060), PLR (p = 0.070) and T stage (p = 0.059) showed weak associations. Other parameters were not found to be in correlation with OS. Next, all the factors with a P value less than 0.10 in univariate analysis were included in multivariate analysis (Table [4](#T4){ref-type="table"}). In multivariate analyses, we demonstrated that MPV was an independent prognostic factor in patients with MIBC (hazard ratio (HR): 2.023 \[95% confidence interval (CI): 1.050-3.897, p =0.025\]).

###### Result of the univariate analysis of overall survival in patients with bladder cancer

                                      Hazard ratio   95% CI        P-value
  ----------------------------------- -------------- ------------- ----------
  Age (years) (≥ 65 versus \< 65)     2.263          1.336-3.831   0.002
  Gender (male versus female)         0.569          0.270-1.200   0.138
  Smoker (yes versus no)              1.019          0.515-2.014   0.957
  BMI (kg/m^2^)                       0.957          0.879-1.042   0.311
  FPG (mmol/L)                        0.879          0.564-1.370   0.569
  WBC (×10^9^/L)                      1.064          0.978-1.158   0.148
  Hemoglobin (g/dl)                   1.002          0.987-1.018   0.778
  Platelet count (×10^9^/L)           1.000          0.996-1.004   0.945
  MPV (fL) (≤ 9.1 versus \> 9.1)      2.274          1.226-4.217   0.009
  PDW (%)                             0.833          0.631-1.101   0.199
  NLR                                 1.082          0.997-1.175   0.060
  PLR                                 1.004          1.000-1.008   0.070
  Histology Grade                                                  
   (G3 versus G1+G2)                  3.482          1.995-6.078   \< 0.001
  Lymphovascular invasion                                          
   (Yes versus No)                    3.262          1.925-5.527   \< 0.001
  Multiplicity                                                     
   (Multifocal versus Solitary)       0.696          0.405-1.196   0.189
  Growth Pattern                                                   
   (Papillary versus Non-papillary)   0.374          0.198-0.706   0.002
  T stage                                                          
   (T3+T4 versus T2)                  1.648          0.982-2.765   0.059
  Chemotherapy (yes versus no)        0.802          0.380-1.691   0.562

**Abbreviations:** see to Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### Result of the multivariate analysis of overall survival in patients with bladder cancer

                                      Hazard ratio   95% CI        P-value
  ----------------------------------- -------------- ------------- ----------
  Age (years) (≥ 65 versus \< 65)     1.785          1.037-3.074   0.031
  MPV (fL) (≤ 9.1 versus \> 9.1)      2.023          1.050-3.897   0.025
  NLR                                 1.000          0.994-1.007   0.892
  PLR                                 1.062          0.923-1.223   0.402
  Histology Grade                                                  
   (G3 versus G1+G2)                  3.404          1.902-6.090   \< 0.001
  Lymphovascular invasion                                          
   (Yes versus No)                    3.272          1.805-5.933   \< 0.001
  Growth Pattern                                                   
   (Papillary versus Non-papillary)   0.419          0.208-0.841   0.014
  T stage                                                          
   (T3+T4 versus T2)                  0.546          0.288-1.037   0.064

CI, confidence interval. Abbreviations: see to Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

DISCUSSION {#s3}
==========

This study found that MPV is correlated with patient's survival and is an independent risk factor for prognosis. Our findings suggested the potential importance of assessing bladder cancer prognosis by combining clinicopathological characteristics with platelet index.

Thrombocytosis is associated with reduced survival in several cancers, such as lung cancer, ovary cancer, endometrium cancer, rectum cancer, kidney cancer, gastric cancer, pancreas cancer, and breast cancer. Increased platelets facilitate cancer progression and metastasis by promoting angiogenesis and tumor cell establishment at distant sites \[[@R17]\]. For bladder cancer, elevated expression of platelet-derived endothelial cell growth factor is markedly correlated with the tumor progression of bladder cancer \[[@R18]\]. Moreover, platelet-derived growth factor receptor beta is found to be a biomarker for predicting NMIBC recurrence \[[@R19]\]. However, these indices for reflecting activated platelets were expensive and not commonly evaluated in the clinical setting. In accordance with the studies above, the present study indirectly confirmed the findings using a simple marker of platelet activation.

Inflammation may be responsible for the association between MPV and survival. There is a strong linkage between inflammation and cancer \[[@R20]\]. Moreover, platelet plays an essential role in inflammation and cancer. MPV is an early parameter of activated platelets. Large platelets are more reactive than their smaller counterparts in releasing a variety of pro-inflammatory cytokines, and are more likely to aggregate. The aggregation at sites of inflammation leads to the intensive infiltration of large platelets into vascular and intestinal wall, and the reduction of platelet size \[[@R21]\]. On the other hand, the release rate of small size platelets from the bone marrow increased since excessive pro-inflammatory cytokines interfere with megakaryopoiesis \[[@R22]\]. Therefore, lower MPV values could be suggestive of an enhanced consumption of large platelets in inflammatory states \[[@R9]\]. Recent reports confirmed that low levels of MPV are associated with high-grade inflammatory diseases and reverse in the course of anti-inflammatory therapy \[[@R9]\].

In agreement with our results, Inagaki N and Kumagai S *et al* found that low MPV level was associated with poor prognosis in non-small-cell lung cancer \[[@R12], [@R23]\]. Aksoy *et al* reported that solid tumors with bone marrow metastasis were more likely to have low MPV levels \[[@R24]\]. These data are also consistent with the current knowledge that anti-platelet is considered to be a part of cancer adjuvant therapy \[[@R2]\].

This is the first time to investigate the correlation between MPV and clinicopathologic parameters, as well as prognosis in patients with MIBC. In addition, we established platelet activation in MIBC using an inexpensive laboratory indicator. Further experiments are needed to elucidate the underlying mechanism. Activated platelets may be considered as an excellent therapeutic target for MIBC patients. However, there are several limitations in our study. First, this study was retrospective and further prospective studies are needed to confirm and update our conclusion. Second, we were unable to explore the exact mechanism of decreased MPV in bladder cancer. Third, the cases were composed of Chinese. The application to other ethnic groups still needs further investigation.

In conclusion, reduced MPV has prognostic value in MIBC patients. Future studies need to be focused on the underlying mechanisms of MPV in MIBC.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

This study consisted of 218 consecutive MIBC cases (mean age 63.2 ± 9.0 years, range 31-82 years). Cases were admitted to Harbin Medical University Cancer Hospital, Harbin Medical University between January 2009 and December 2009. All patients undergone radical cystectomy. The pathologic diagnoses of MIBC were evaluated by pathologists from biopsy reports. None of the patients received preoperative chemotherapy or radiation therapy. Patients were excluded if they had hematological disorders, coronary artery disease, hypertension, diabetes mellitus, and medical treatment with anticoagulant, statins, and acetylic salicylic acid. Standard demographic and clinicopathological data were collected from the patients' records in hospital. Survival data were obtained through follow-up. Overall survival (OS) was defined as the interval from the date of diagnosis to death or last follow-up. The median follow-up time was 60 months.

Venous blood samples after an 10-hour overnight fasting were collected from the individuals within 1 week prior to surgery. White blood cell (WBC), haemoglobin, and platelet indices were measured by an autoanalyzer (Sysmex XE-2100, Kobe, Japan). The whole blood samples were collected in EDTA-containing tubes, and all samples were processed within 30 minutes after blood collection. The platelet-to-lymphocyte ratio (PLR) was calculated as the absolute platelet count measured in × 10^9^/L divided by the absolute lymphocyte count measured in ×10^9^/L. The neutrophil-to-lymphocyte ratio (NLR) was calculated as the absolute neutrophil count measured in × 10^9^/L divided by the absolute lymphocyte count measured in × 10^9^/L.

The Institutional Ethics Review Board of Harbin Medical University Cancer Hospital of Harbin Medical University approved this study prior to commencement of data collection and waived the informed consent requirement because it was a retrospective study.

Statistical analysis {#s4_2}
--------------------

All continuous data are expressed as means ± SD or medians (interquartile range), and the categorical data are expressed in percentages. The continuous variables were compared with Student's t test or the Mann-Whitney U test, as appropriate, whereas categorical variables were compared with the Chi-square test. The Kaplan-Meier method was used for descriptive analysis of survival curves; survival curves were compared using log-rank tests. We used the univariate Cox proportional hazards model for identifying the contribution of each variables. The multivariate Cox proportional hazards models were used to determine adjusted hazard ratios for survival. Variables with P-values \< 0.1 were selected for the multivariate analysis. Receiver-operating characteristics (ROC) curve analysis was performed to identify cut-off value of MPV. P \< 0.05 was considered to indicate statistically significant differences in all tests. All statistical analyses were performed using SPSS Statistics version 22.0 (SPSS Inc., Chicago, IL, USA).

**CONFLICTS OF INTEREST**

The authors declare no conflict of interest.

**GRANT SUPPORT**

This work was supported financially by grants from the Harbin Medical University Cancer Hospital (JJZD2017-05) and postdoctoral research project of Heilongjiang Province (No. LBH-Z16190).
